Microcirculation in hypertension: a new target for treatment?
Levy
B I
BI
INSERM Unit 141, IFR Circulation, Hôpital Lariboisière, Paris, France.
Ambrosio
G
G
Pries
A R
AR
Struijker-Boudier
H A
HA
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008833:Microcirculation / Q000187:drug effects*; D051381:Rats; D011918:Rats, Inbred SHR
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics; D000804:Angiotensin II